Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE AF versus LABETALOL HYDROCHLORIDE IN DEXTROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE AF versus LABETALOL HYDROCHLORIDE IN DEXTROSE.
BETAPACE AF vs LABETALOL HYDROCHLORIDE IN DEXTROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sotalol is a class III antiarrhythmic agent that also has non-cardioselective beta-adrenergic receptor blocking activity. It prolongs the cardiac action potential duration by blocking potassium channels (IKr), thereby prolonging the QT interval and refractory periods.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
80 mg orally twice daily. For atrial fibrillation/flutter, initiate at 80 mg twice daily; may increase after 2-3 days to 120 mg twice daily if needed. Maximum 120 mg twice daily.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–20 hours) in patients with normal renal function; prolonged in renal impairment (up to 42 hours in severe impairment).
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Primarily renal (unchanged drug and metabolites); approximately 40% excreted as unchanged sotalol in urine, with additional metabolites via fecal route (~10%). Biliary excretion minimal (<5%).
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Category C
Category A/B
Beta-Blocker
Alpha/Beta-Blocker